Tradjenta (linagliptin) is a once-daily 5 mg oral tablet approved by the FDA in May 2011 for adults with type 2 diabetes. Boehringer Ingelheim and Eli Lilly co-developed and co-marketed the drug. Linagliptin works by blocking the DPP-4 enzyme, which causes the body's natural incretin hormones (GLP-1 and GIP) to remain active longer after meals, suppressing glucagon and supporting insulin release in a glucose-dependent manner. Unlike some older diabetes drugs, linagliptin is cleared primarily by the liver and does not require renal dose adjustment, which makes it a common choice for patients with reduced kidney function. The combination tablets Jentadueto (linagliptin plus metformin) and Jentadueto XR (extended-release) and the SGLT2-plus-DPP4 combination Glyxambi (linagliptin plus empagliflozin) use the same active ingredient.
Tradjenta's 2026 list price runs approximately $630 per month at the pharmacy counter. Boehringer Ingelheim has protected the drug with an extensive patent portfolio, and despite an FDA tentative approval of a generic linagliptin in 2021, no generic has reached US pharmacy shelves as of June 2026. The absence of generic competition keeps cash prices high for patients without insurance or whose plan does not cover the drug. Patients with Medicare Part D should be aware that the IRA negotiated price of $78 per month for Tradjenta does not take effect until January 1, 2027. In 2026, Medicare Part D enrollees remain subject to their plan's formulary tier and the general $2,100 annual out-of-pocket cap across all Part D drugs. Patients combining Tradjenta with metformin often have Jentadueto as a formulary option, which may be tiered differently than standalone Tradjenta. For patients considering an SGLT2 inhibitor such as Jardiance or Farxiga as an alternative, these drugs also carry prior authorization requirements on most commercial plans.
Two programs from Boehringer Ingelheim can meaningfully lower Tradjenta cost in 2026. Commercially insured patients who pay more than $10 per fill out of pocket can use the Tradjenta Savings Card to reduce their cost-share to $10 per 30-day, 60-day, or 90-day supply. Uninsured and underinsured patients at or below 400 percent of the federal poverty level may apply to the BI Cares Foundation patient assistance program, which can supply Tradjenta free of charge. Patients with Medicare, Medicaid, TRICARE, or VA coverage cannot legally use the manufacturer coupon but can use the income-based patient assistance program instead. Patients who qualify for Medicaid typically pay $1 to $4 per prescription under the nominal Medicaid copay structure, which varies by state.
What Tradjenta Costs by Point of Pay (2026)
The price you pay depends almost entirely on WHERE you pay. The same tradjenta can cost many times more at a hospital than at your local pharmacy:
2026 Tradjenta Price by Point of Pay| Where you pay | Typical cost | Notes |
|---|
| Pharmacy counter (retail, cash, no insurance) | $625 to $760 per month (2026) | List price without any discount card or insurance. GoodRx brings it to approximately $278 at select pharmacies. |
| Medicare Part D (2026, before 2027 MFP) | $0 to $200 per month, capped at $2,100 per year | Covered for type 2 diabetes. Tier and copay vary by plan. The $78 IRA Maximum Fair Price takes effect 2027-01-01. |
| Commercial insurance with Boehringer Ingelheim savings card | $10 per fill (30-, 60-, or 90-day supply) | Available to commercially insured patients only. Not valid with Medicare, Medicaid, TRICARE, or VA. |
| BI Cares Foundation patient assistance program | $0 (free) for eligible uninsured/underinsured patients | Income at or below 400% FPL; must be uninsured or have Medicare without adequate drug coverage. |
| Medicaid | $1 to $4 per prescription (nominal copay) | Covered for type 2 diabetes in most state Medicaid programs. Prior authorization may be required. Copay varies by state. |
Retail prices reflect 2026 GoodRx and pharmacy survey data. Part D ranges depend on your plan's formulary tier and where you are in your benefit year. The IRA Maximum Fair Price of $78 for Tradjenta applies beginning January 1, 2027.
Source: GoodRx 2026, CMS Part D 2026 benefit parameters, Boehringer Ingelheim savings programs, CMS IRA IPAY 2027 negotiated prices
Why Hospitals Charge So Much
Tradjenta is an outpatient oral tablet prescribed for chronic blood sugar management. Patients almost never receive it in a hospital setting as an administered drug. When Tradjenta appears on an inpatient hospital bill, it is usually because a hospitalized diabetic patient brought their own supply, and the facility pharmacy dispensed a replacement dose during the stay. In that scenario, the charge can easily run two to four times the retail price. Hospitals apply facility fee markups, pharmacy handling fees, and compounding charges even for oral tablets that require no preparation beyond handing a pill to the patient. A 30-tablet pack that retails for $630 at the pharmacy counter may be billed at $900 to $2,200 on an itemized hospital bill.
Three structural factors drive hospital pharmacy markups on oral diabetes medications. First, hospitals operate under charge master pricing that sets list charges independent of acquisition costs. The actual hospital acquisition cost for a 30-day supply of Tradjenta is generally close to the wholesale acquisition cost ($630), but the charge master rate applied to the bill may be 40 to 250 percent higher. Second, prior authorization and formulary appeals are handled differently in inpatient settings, meaning costs get passed through without the insurer's negotiated discount applying automatically. Third, facility fees are charged on top of drug costs when the dispensing event is associated with an inpatient stay. If you see Tradjenta on an itemized bill above $800 for a 30-day supply equivalent, request an itemized charge breakdown by National Drug Code (NDC), compare to the 2026 wholesale acquisition cost, and file a billing dispute with the hospital's patient financial services office.
Patient Assistance Programs
Boehringer Ingelheim offers two separate cost-reduction programs for Tradjenta in 2026: a commercial savings card for insured patients and an income-based patient assistance program for uninsured and underinsured patients. The savings card reduces your cost-share to $10 per fill for commercially insured patients. The BI Cares Foundation patient assistance program can supply Tradjenta free of charge for patients at or below 400 percent of the federal poverty level who lack adequate prescription drug coverage. These two programs serve different populations and cannot be stacked.
Patient assistance programs for Tradjenta| Manufacturer program | Cost / Benefit | How to apply |
|---|
| Tradjenta Savings Card (Boehringer Ingelheim) | $10 per 30-, 60-, or 90-day supply for commercially insured patients. Card covers up to $150 per fill. | patient.boehringer-ingelheim.com/us/products/tradjenta/savings-card-print |
| BI Cares Foundation Patient Assistance Program | Free Tradjenta for uninsured or Medicare patients at or below 400% FPL. Drug shipped directly to your home or prescriber. | boehringer-ingelheim.us/our-responsibility/patient-assistance-program |
| NeedyMeds Drug Discount Card | Variable discount on Tradjenta accepted at most US pharmacies; no income or insurance requirements. | needymeds.org |
Manufacturer savings cards cannot be used by Medicare, Medicaid, TRICARE, or VA beneficiaries under federal anti-kickback law (42 U.S.C. 1320a-7b). If you have government health coverage, apply for the BI Cares Foundation patient assistance program instead of the savings card. The patient assistance program is available to Medicare beneficiaries who lack adequate prescription drug coverage and meet the income threshold.
Source: Boehringer Ingelheim patient program pages, NeedyMeds.org, BI Cares Foundation
Medicare Part D
Tradjenta is a Medicare Part D drug, covered for adults with type 2 diabetes. In 2026, your total annual out-of-pocket cost across all Part D drugs combined is capped at $2,100 under the Inflation Reduction Act. Once you reach $2,100 in out-of-pocket Part D spending in a calendar year, you pay $0 for the rest of the year on covered drugs, including Tradjenta. Most Part D plans that cover Tradjenta place it on a mid-tier formulary level, typically Tier 3 or Tier 4, which means copays before the catastrophic threshold can run $50 to $120 per fill depending on the plan. Patients enrolled in Extra Help (Low-Income Subsidy) from Medicare pay dramatically less, often $3 to $10 per fill, and are not subject to the full out-of-pocket phase.
Starting January 1, 2027, Medicare beneficiaries will pay a Maximum Fair Price of $78 per 30-day supply of Tradjenta. This represents an 84 percent reduction from the current list price and results from the second round of IRA drug price negotiations (IPAY 2027), which CMS announced in November 2025. Tradjenta's ceiling was set at the Part D net price of approximately $194 rather than the statutory discount formula, because rebates from the list price were among the highest in the cohort at 58 percent. The practical impact: in 2026, Medicare patients still pay standard plan rates. In 2027, that exposure drops sharply for most enrollees. Patients who are approaching the 2026 formulary coverage gap should speak with their plan about the Medicare Prescription Payment Plan, which spreads Part D out-of-pocket costs evenly across the calendar year.
Medicare plans are not required to include Tradjenta on their formulary if another DPP-4 inhibitor or competing class drug (SGLT2 inhibitor, GLP-1 receptor agonist) is available. If Tradjenta is not on your plan's formulary in 2026, your prescriber can file a formulary exception request documenting a medically necessary reason you require linagliptin specifically (for example, renal impairment that makes other agents less appropriate). Prior authorization is commonly required even when Tradjenta is covered, and step therapy requiring trial of a first-line oral agent such as metformin is standard before coverage is authorized. Patients who qualify for Medicaid typically pay $1 to $4 per Tradjenta prescription under the state's nominal copay structure, which varies by state and may vary by recipient category.
Common Tradjenta Billing Errors
If you received a bill for Tradjenta above $200 per month with commercial insurance, or above $150 per month on Medicare Part D, check for these issues before paying:
- Prior authorization not submitted or expired: most commercial and Medicare Part D plans require PA for brand-name DPP-4 inhibitors. If your prescriber did not submit or renew prior authorization, the plan defaults to the full cash price.
- Savings card not applied at the pharmacy counter for commercially insured patients. The Boehringer Ingelheim savings card reduces your cost-share to $10, but the pharmacist must scan the card's BIN and PCN numbers at the register.
- Jentadueto billed separately from metformin when the combination tablet was prescribed: Jentadueto is a single combination product and should be billed as one fill, not as two separate medications.
- Charged at the non-formulary rate when the drug should be on-formulary: confirm with your plan whether Tradjenta is on your formulary and at what tier. A formulary exception or tier exception request can reduce your cost-share.
- Billed for the 2026 list price after the 2027 MFP takes effect starting January 1, 2027: once the IRA Maximum Fair Price of $78 is effective, Medicare plans must apply that rate. Report billing above $78 per month for Tradjenta to your plan or to 1-800-MEDICARE after January 1, 2027.
Frequently Asked Questions
Is there a generic for Tradjenta in 2026?
No. No generic linagliptin is commercially available at US pharmacies as of June 2026. The FDA granted tentative approval to a generic in 2021, but Boehringer Ingelheim's patent portfolio continues to block commercial market entry. CMS has noted that generic competition may arrive later in 2026 or in 2027, which is why Tradjenta was flagged for potential removal from the IRA negotiation list in future cycles. Ask your pharmacist in late 2026 whether a generic has become available. Tradjenta is a small-molecule drug and is not a biologic, so biosimilars are not applicable.
How do I apply for the BI Cares Foundation patient assistance program for Tradjenta?
Call 1-800-556-8317 or visit the Boehringer Ingelheim patient assistance page to download the application. Both the patient and prescriber sections must be completed and signed. Required documents include proof of income (tax return or pay stubs), proof of US residency, a valid Tradjenta prescription, and a statement confirming you have no adequate prescription drug coverage. Mail the completed application to BI Cares Foundation, PO Box 99055, Jeffersontown, KY 40296. Processing takes 7 to 14 business days. If approved, Tradjenta ships free directly to your home. Annual renewal is required with updated income documentation.
Can I use the Tradjenta savings card with Medicare?
No. Federal anti-kickback law (42 U.S.C. 1320a-7b) prohibits manufacturer copay savings cards from being used by anyone enrolled in Medicare, Medicaid, TRICARE, or VA benefits. The Boehringer Ingelheim Tradjenta savings card is valid only for commercially insured patients who are not covered by any government health program. If you have Medicare, your options are the BI Cares Foundation patient assistance program (free drug for incomes at or below 400 percent FPL), the Extra Help Medicare program (Low-Income Subsidy), or the general Medicare Part D formulary coverage with the $2,100 annual out-of-pocket cap.
What does Tradjenta cost without insurance at the pharmacy counter in 2026?
The cash retail price for Tradjenta 5 mg (30 tablets, 30-day supply) runs approximately $625 to $760 per month in 2026 depending on the pharmacy. With a GoodRx coupon, the price at major chains such as CVS, Walgreens, and Walmart drops to approximately $278 per month. Applying the Boehringer Ingelheim savings card reduces cost further to $10 per fill for commercially insured patients. Uninsured patients who do not qualify for the savings card should apply for the BI Cares Foundation patient assistance program before paying full cash price.
Does the IRA negotiated price for Tradjenta apply in 2026?
No. The IRA Maximum Fair Price of $78 per 30-day supply for Tradjenta was negotiated under the Inflation Reduction Act's second round (IPAY 2027) and takes effect January 1, 2027, not January 1, 2026. In 2026, Medicare Part D enrollees pay standard plan rates for Tradjenta, subject only to the general $2,100 annual out-of-pocket cap across all Part D drugs combined. The $78 price represents an 84 percent reduction from the current list price and will apply automatically to Medicare Part D plans beginning in 2027. CMS announced the negotiated prices in November 2025.
What if my insurance denies coverage for Tradjenta?
Request a written denial notice and file a formal internal appeal within 60 days. Include a medical necessity letter from your prescriber explaining why linagliptin is required. Ask your prescriber to request a peer-to-peer review with the plan's medical director. If the internal appeal fails, escalate to an external independent review through your state Department of Insurance. If you have a renal impairment diagnosis, document it clearly, as linagliptin's lack of renal dose-adjustment requirement is a strong clinical rationale. If all appeals fail, apply for the BI Cares patient assistance program (free drug for incomes at or below 400 percent FPL).
Do I qualify for the BI Cares patient assistance program for Tradjenta?
You likely qualify if your household income is at or below 400 percent of the 2026 federal poverty level and you are uninsured or lack adequate prescription drug coverage. For a household of one, that means annual income at or below $63,840 in 2026. For a household of four, the threshold is $132,000. You must be a US citizen or legal resident, have a valid Tradjenta prescription from a US-licensed prescriber, and not have active commercial prescription drug insurance that covers Tradjenta. Medicare beneficiaries without adequate drug coverage may also qualify. Income thresholds are based on 2026 federal poverty guidelines published by HHS at aspe.hhs.gov.
How does Tradjenta compare to Januvia (sitagliptin) on cost in 2026?
Both Tradjenta (linagliptin) and Januvia (sitagliptin) are DPP-4 inhibitors for type 2 diabetes with similar mechanisms and comparable blood sugar outcomes. However, their 2026 cost picture is very different. Januvia has an IRA Maximum Fair Price of $113 per month effective January 2026 and a generic (sitagliptin) that began launching in May 2026 for approximately $60 to $120 per month with coupons. Tradjenta's IRA price of $78 per month does not take effect until January 2027, and no generic linagliptin is available yet. Clinically, linagliptin has the advantage of requiring no renal dose adjustment. For patients with normal kidney function whose plan covers sitagliptin at a lower tier, generic sitagliptin is likely the more affordable option in 2026.
